The TRIUMPH programme is evaluating retatrutide across multiple indications including chronic weight management, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and MASLD
Products Data Briefs Number 313 July 2018
#CredibleConversations To view or add a comment, sign in On September 5th, the U.S
Longer treatment duration
They have a great variety of uses for things like acne control, menstrual regulation
This FDA-approved treatment, commonly known by its brand name Zepbound, offers a significant advantage for those battling obesity